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 $%675$&7 Combretastatin A-4 (CA-4) (1) is a plant-derived anticancer agent binding to the tubulin 
colchicine site. Polyunsaturated fatty acids (PUFA) are readily taken up by cancer cells and have been 
used to improve cell targeting. In the present study, four CA-4-PUFA conjugates were synthesized by 
coupling combretastatin A-4 (1) with several polyunsaturated fatty acids. The conjugates (2a-d) were 
characterized using spectroscopic methods. Their cytotoxicity was evaluated against human breast cancer 
cells (MCF-7) and the inhibition of tubulin polymerization was determined in vitro. All conjugates 
influenced tubulin polymerization with the arachidonic acid conjugate (2c) displaying cytotoxicity similar 
in potency to the natural product CA-4 (1). 
  
 Microtubules are polymeric intracellular structures composed of tubulin and are important for a variety of 
cellular functions, including intracellular transport, maintenance of cell shapes and cell division.1 During 
cell division, microtubules form the mitotic spindle in which the dynamics are highly sensitive to 
microtubule-binding agents. Modification of microtubule dynamics has been among the most promising 
approaches in the search for new and more efficient cytotoxic drugs and has led to the development of 
tubulin-binding agents such as the taxanes and vinca alkaloids, which stabilize or destabilize 
microtubules.2 However, the search for new agents demonstrating improved cancer cell specificity, less 
neurotoxicity and increased efficacy in chemoresistant cancer cells is still ongoing.3 Combretastatins hold 
considerable promise in this regard, offering a potential wider therapeutic window or activity against 
multi-drug-resistant cancer cells,4 and much effort has been made to develop them as novel tubulin-
binding agents for cancer chemotherapy. 
     The combretastatins are a class of natural stilbene derivatives isolated from the bark of the South 
African bush willow tree Combretum caffrum Kuntze (Combretaceae).5 The cis-stilbenoid derivative 
combretastatin A-4 (CA-4, 1) (Figure 1) was found to be the most potent among this class of natural 
products 6 and the search for more effective analogues has led to the development of numerous 
derivatives,4c, 7 including amino derivatives 8 such as combretastatin A-4 amine and its serine prodrug 
AVE8062, which has shown improved pharmacological activities when compared to the natural product. 
Water-soluble analogues such as combretastatin A-4 phosphate,9 and combretastatin A-1 phosphate 10 
have also been developed and have been used in different clinical trials either on their own or as part of 
combination therapy. Mechanistically, CA-4 and its derivatives are potent inhibitors of microtubule 
polymerization, leading to arrest in the G2/M-phase and subsequent apoptotic cell death.
11 In addition to 
their cytotoxic effects on cancer cells,4c, 7b, 11a combretastatins exert a selective effect on proliferating 
endothelial cells leading to a substantial vascular-disruptive activity  on tumor blood vessels.4b, 6, 12 
 Although CA-4 and its analogues have demonstrated their potential as cancer chemotherapeutic agents, 
they are not completely devoid of some of the problems associated with treatments using cytotoxic 
vascular-disrupting agents. Indeed, cardiac toxicity has been identified as a dose-limiting toxicity for CA-
4 analogues in several phase I clinical trials.9c, 11a, 13 Selective tumor targeting of cytotoxic agents is one 
of the most effective protocols developed to alleviate many of the unwanted side effects encountered with 
untargeted chemotherapy.14 Developing a method to selectively deliver combretastatins into cancer cells 
could minimize some of the associated side effects. 
 
 
Figure 1. Structures of Combretastatin-type Anti-Tubulin Agents 
 
     Polyunsaturated fatty acids (PUFAs) are important nutritional constituents of dietary vegetable oils and 
cold water fish and therefore are considered to be safe. Studies have shown that there is a selective uptake 
of PUFAs into cancerous cells compared to healthy cells and that the incorporation of PUFAs into the 
lipid bilayer of the cancer cells disrupts their membrane structure and fluidity, which as a result seems to 
modify their chemosensitivity.15 In the context of targeted therapies, conjugation of PUFAs to 
 conventional cytotoxic drugs has been a promising strategy 16 with Taxoprexin (paclitaxel/ 
docosahexaenoic acid) reaching phase III clinical trials.17 Applying this same general concept to 
combretastatins could minimize some of the unwanted side effects and improve their therapeutic indices. 
     Herein are reported the synthesis of four combretastatin A-4/polyunsaturated fatty acid (CA-4-PUFA, 
2a-d) conjugates (Scheme 1) and their biological effects on human breast cancer cells (MCF-7) and 
microtubule polymerization. 
 
Scheme 1. Synthesis of Combretastatin A-4-PUFA Conjugates 
 
(i) Ac2O, TEA, reflux, 3 h (ii) Cu, C9H7N, 210 °C, 2 h (iii) linoleic acid (2a), linolenic acid (2b), 
arachidonic acid (2c), docosahexaenoic acid (2d), DIC, DMAP, CH2Cl2, r.t., overnight. 
 
     Studies have shown that the cis configuration of the stilbene unit is required for highest compound 
cytotoxic potency.7b, 18 Z-Combretastatin A-4 (1) was therefore synthesized, in a 41% overall yield, using 
the stereoselective Perkin condensation method of Gaukroger et al. with subsequent decarboxylation 18 
 (Figures S1 and S2, Supporting Information). The alkene bridge proton signals occurred as two doublets 
at 6.47 ppm and 6.38 ppm (J = 12.0 Hz), which is distinctive of vicinal olefinic protons and indicative of 
a cis-stilbene (Figure S2a, Supporting Information). Indeed, cis coupling is expected between 6 and 12 Hz 
and trans between 12 and 18 Hz. Further data on the geometrical isomerism was gained from the UV 
spectra of CA-4 (1) and compound 3. Beale et al. and others have shown that trans and cis stilbenes can 
be identified by UV spectroscopy.19 Extinction coefficients (lRJİREWDLQHGIURP89VSHFWUDDUHPXFK
greater for stilbenes with structures where the aromatic moieties are trans WRHDFKRWKHU ORJİa
compared with those with cis DURPDWLFULQJVORJİa19 Extinction coefficients were calculated for 
intermediate 3 and CA-4 (1) from their UV spectrum (Figures S1d and S2e, Supporting Information) and 
ZHUHIRXQGWREHORJİ DQGORJİ UHVSHFWLvely. This is in agreement with the literature and 
confirmed that the synthesized CA-4 (1) has a cis configuration. With CA-4 in hand, conjugation to 
PUFAs was accomplished using the Steglich esterification method to give CA-4-PUFA conjugates (2a-
d) with yields between 57-90%. The synthesized compounds were characterized by HRMS, 1H NMR, 13C 
NMR and IR spectroscopy (Figures S3-S6, Supporting Information). 
     Combretastatin A-4 has demonstrated some cytotoxic activity towards various cancer cells.4a, 7b, 11a 
Interference with the cellular microtubule dynamics generally leads to cell-cycle arrest and cell death via 
mitotic catastrophe, although other studies have demonstrated an apoptotic effect.6 The cytotoxicity of 
compounds 2a-2d was evaluated against the MCF7 human breast cancer cell line using an MTS assay 
(Figure 2).  The cells were treated with different concentrations of each substance (0 ± ȝ0DQGWKHLU
metabolic activity was evaluated after 72 h. The antiproliferative activity of CA-4 (1) was confirmed with 
an IC50 YDOXHRIȝ0LQJRRGDJUHHPHQWZLWKWKHOLWHUDWXUH20 One of the first PUFA conjugates was 
developed by Bradley et al.16a who conjugated docosahexaenoic acid (DHA) to paclitaxel. In vitro, the 
PUFA analogue was less active by three orders of magnitude. However, in vivo, the conjugate 
 demonstrated increased antitumor activity when compared with paclitaxel due to an improved 
pharmacokinetic profile. Since then, other potential PUFA anticancer agents have been synthesized (e.g. 
curcumin, phenstatin, doxorubicin) and have displayed various activities against cancer cells.16b-e, 21 
     In the present study, four CA-4 conjugates were synthesized using four different PUFA derivatives 
(i.e., linoleic acid, linolenic acid, arachidonic acid and docosahexaenoic acid) (Scheme 1).  The 
arachidonic acid conjugate (2c) displayed the highest in vitro activity and showed some concentration 
dependent potency similar to the natural product (1) with an IC50 RIȝ07KHRWKHUFRQMXJDWHV2a, 2b 
and 2d) also displayed some cytotoxicity (~ 65-75% cell viability) but at higher concentrations (5-ȝ0
(Figure 2).  These results are consistent with the reduction of in vitro activity also observed for other 
















Figure 2. Antiproliferative effects of CA-4 and PUFA analogues for MCF-7 human breast cancer cells. 
The cells (5,000 cells/well) were treated with different concentrations of the test compounds 
[combretastatin A-4 (1), linoleic acid conjugate (2a); linolenic acid conjugate (2b); arachidonic acid 
conjugate (2c) and docosahexaenoic acid conjugate (2d)] and their metabolic activity was assessed after 
72 h using an MTS assay. Viability of the MCF-7 cells was determined relative to untreated cells. Mean 
values ± SEM, n = 18. 
 
     The cytotoxicity of CA-4 (1) has been associated generally with the inhibition of microtubule formation 
GXHWRWKHELQGLQJRIWKHFRPSRXQGWRWKHFROFKLFLQHELQGLQJVLWHRQȕ-tubulin2. Structure-activity studies 
have identified chemical features linked to the activity of the molecule.4a, 5 Whereas the cis configuration 
and the trimethoxybenzene moiety on the A ring are essential for high cytotoxicity and efficient tubulin 
binding, the B ring is amenable to structural modifications. Indeed, studies have indicated that the 4-
methoxy substituent is important but that the substituent at the C-3' position (Figure 1) can be modified 
without loss of activity.4a, 7b, 8, 22 In this context, some CA-4 derivatives have displayed cytotoxicity 
without any in vitro tubulin activity.7b, 7d, 23 This has also been observed with DHA paclitaxel conjugates.16a 
      To determine if the antiproliferative activities of the conjugates produced herein correlated with their 
LQWHUDFWLRQ ZLWK ȕ-tubulin, the effect of the synthesized CA-4-PUFAs on tubulin 
polymerization/depolymerization was determined in vitro, using a turbidity assay 20b (Figure 3). The 
amount of tubulin polymerized is directly proportional to the area under the curve (AUC). To quantify the 
conjugates' effect on tubulin polymerization when compared to CA-4 (1), the AUCs of the samples were 
normalized to that of combretastatin A-4. Values above 1.0 indicated a lower inhibition of microtubule 
polymerization. At low coQFHQWUDWLRQȝ0DOOFRQMXJDWHVGLVSOD\HGDSURILOHVLPLODUWR1 (Figures 3a 
and 3c). The lag time for the onset of the tubulin polymerization was between 15-20 min, followed by a 
similar rate of microtubule propagation. These results also indicated that, contrary to DHA paclitaxel, the 
in vitro toxicity of 2c, which displayed similar activity to 1 (Figure 2), seems to correlate with its 
LQWHUIHUHQFHZLWKWXEXOLQSRO\PHUL]DWLRQ$WWKHKLJKHVWFRQFHQWUDWLRQȝ0LWZDVDSSDUHQWWKDWDOO
compounds displayed a lower inhibitory activity compared to CA-4 (1) (Figures 3b and 3c). 
 Figure 3. In vitro tubulin polymerization curves in the presence of combretastatin A-4 (1) and 
combretastatin A-38)$DQDORJXHVDWFRQFHQWUDWLRQVRIȝ0DDQGȝ0E$UHD under the curves 
of the conjugates (* p < 0.05) (c). [Combretastatin A4 (CA-4, 1), CA-4 linoleic acid conjugate (2a); CA-
4 linolenic acid conjugate (2b); CA-4 arachidonic acid conjugate (2c) and CA-4 docosahexaenoic acid 
conjugate (2d)]. Tubulin polymerizDWLRQ>7XEXOLQ@ ȝ0PJP/ZDVIROORZHGDW&E\
measuring the turbidity variation at 350 nm every 30 sec for 2 h. Nocodazole and DMSO were used as 
controls. Assays were performed in duplicate. Statistical analysis: one way analysis of variance with 
Bonferroni post-test. 
 
 EXPERIMENTAL SECTION 
     General Experimental Procedures. Reactions were carried out in oven-dried glassware and moisture-
sensitive procedures were performed under N2. Melting points were measured using capillary tubes on a 
Stuart SMP3 instrument and are uncorrected. UV spectra were acquired on a Shimadzu UV-1700 
spectrophotometer. The extinction coefficients of 3 (4.16 x10-5 M) and 1 (3.55 x10-5 M) were determined 
at the maximum wavelength using methanol as the solvent. IR spectra were obtained on a Perkin Elmer 
Spectrum One FTIR spectrometer (ATR). 1H NMR spectra and 13C NMR spectra were obtained on a 
Varian NMR spectrometer at 400 MHz and 101 MHz or 500 MHz and 126 MHz, respectively. Chemical 
shifts are relative to TMS. Exact mass measurements and CHN analysis were performed at University 
College London, School of Pharmacy, using a Micromass Q-TOF Premier Tandem mass spectrometer 
and a Carlo-Erba EA 1108 apparatus respectively. Thin-layer chromatography (silica gel 60 UV254 on 
aluminum plates) was used to monitor reactions and was observed under UV light (254 nm and 365 nm), 
or visualized by phosphomolybdic acid (0.1 mg.mL-1 in absolute ethanol) with heating. Column 
chromatography was performed using Merck silica gel 60 (230-400 mesh). 
     (E)-3-(3'-Hydroxy-4'-methoxyphenyl)-2-(3'',4'',5''-trimethoxyphenyl)prop-2-enoic acid (3). 
Compound 3 was synthesized using the method developed by Gaukroger et al.18 A mixture of 3,4,5-
trimethoxyphenylacetic acid (2.00 g, 8.84 mmol), 3-hydroxy-4-methoxybenzaldehyde (0.6 g, 4.4 mmol), 
acetic anhydride (4 mL), and triethylamine (2 mL) was heated under reflux for 3 h.  After acidification 
with concentrated hydrochloric acid (6 mL), the resulting solid was filtered off and recrystallized from 
ethanol to give the propenoic acid derivative (3) as fine yellow needles (950 mg, 60%): yellow needles 
(EtOH); mp 237±&890H2+Ȝmax ORJİQP,5$75Ȟmax 3320, 2941, 1667, 1608, 
1586, 1504 cm-1; 1H NMR (DMSO-d60+]į+ s, COOH), 8.95 (1H, s, ArOH), 7.57 (1H, 
s), 6.81 (1H, d, J = 8.5 Hz), 6.61 (1H, dd, J = 8.6, 2.3 Hz), 6.54 (1H, d, J = 2.3 Hz), 6.44 (2H, s), 3.73 
 (3H, s), 3.72 (3H, s), 3.69 (6H, s); 13C NMR (DMSO-d6, 0+]į
137.0, 132.2, 130.4, 127.1, 122.98, 117.2, 111.5, 106.7, 60.2, 56.0, 55.5; ESIMS m/z 361.2 [M+H]+ (calcd 
for C19H21O7+, 360.1). 
     cis-Combretastatin A-4 (1). Compound 3 (2.00 g, 5.56 mmol) was added to powdered copper (1.84 
g, 28.95 mmol) in quinoline (20 mL, 170 mmol) and the resulting mixture was heated at 210 °C for 2 h. 
Upon cooling, ether (50 mL) was added and the copper was filtered off through Celite. The filtrate was 
washed with 1 M hydrochloric acid and the aqueous layer was recovered and further extracted with 
diethylether. The combined organic layers were washed with saturated sodium carbonate solution, water, 
and brine, dried over MgSO4 and concentrated under a vacuum. Column chromatography (25% ethyl 
acetate in hexane) and recrystallization from ethyl acetate and hexane afforded cis-combretastatin A-4 (1) 
as a pale yellow crystalline solid (1.19 g, 68%): yellow solid (C4H8O2/C6H14); mp 118±119 °C; UV 
0H2+Ȝmax ORJİQP,5$75Ȟmax 3505, 3288, 2995, 2940, 2839, 1579, 1504 cm-1; 1H 
NMR (CDCl3, 400 MHz) į1H, d, J = 2.0 Hz), 6.79 (1H, dd, J = 2.0, 8.0 Hz), 6.73 (1H, d, J = 8.0 
Hz), 6.53 (2H, s), 6.48-6.40 (2H, dd, J = 12.0, 12.0 Hz), 5.53 (1H, s) 3.86 (3H, s), 3.84 (3H, s), 3.70 (6H, 
s); 13C NMR (CDCl3, 101 MHz) į
60.9, 56.0; ESIMS m/z 317.3 [M+H]+; HRESIMS m/z 317.1372 [M+H]+ (calcd for C18H21O5+, 317.1389). 
     Linoleic Acid Conjugate (2a). General method A: A solution of combretastatin A-4 (1) (0.15 g, 0.47 
mmol), linoleic acid (0.324 g, 1.16 mmol) and N, N-diisopropylcarbodiimide (0.183 mL, 1.18 mmol) in 
dry CH2Cl2 (6 mL) was stirred for 15 min under N2. 4-Dimethylaminopyridine (0.017 g, 0.141 mmol) in 
minimal CH2Cl2 was added and the reaction was stirred overnight at room temperature under N2. The 
reaction mixture was transferred into a separating funnel and 20 mL of CH2Cl2 were added, followed by 
washing with water (2 x 20 mL). The organic layer was collected and the aqueous layer further extracted 
with dichloromethane (3 x 20 mL). The combined organic layers were dried over anhydrous MgSO4, 
 filtered and concentrated under vacuum. Column chromatography (40% ethyl acetate - 60% hexane) 
afforded the conjugate (2aDVDQRLOPJ\LHOG,5$75Ȟmax 3006, 2927, 2865, 1763, 1577, 
1508 cm-1; 1H NMR (CDCl3, 0+]į+GJ = 5 Hz), 7.00 (1H, d, J = 0.15 Hz), 6.84 (1H, d, 
J = 8.5 Hz), 6.50 (2H, s), 6.45 (2H, dd, J = 12.2 Hz), 5.39±5.32 (4H, m), 3.83 (3H, s), 3.79 (3H, s), 3.70 
(6H, s), 2.77 (2H, t, J = 6.5 Hz), 2.52 (2H, t, J = 7.5 Hz), 2.07±2.03 (4H, m), 1.72 (2H, quint., J = 7.4 Hz), 
1.38±1.28 (14H, m), 0.89 (3H, t, J = 6.8 Hz); 13C NMR (CDCl3, 0+]į
137.3, 132. 6, 130.3, 130.2, 129.6, 128.7, 128.2, 128.0, 127.7, 123.3, 112.1, 106.0, 61.0, 56.0, 34.1, 31.6, 
29.7, 29.5, 29.28, 29.25, 29.1, 27.3, 25.7, 25.1, 22.7, 14.2; ESIMS m/z 580 [M+H]+; HRESIMS m/z 
579.3658 [M+H]+ (calcd for C36H51O6
+, 579.3686). 
     Linolenic Acid Conjugate (2b). Compound 2b was prepared according to general method A using 1 
(0.15 g, 0.47 mmol), linolenic acid (0.329 g, 1.18 mmol), N, N-diisopropylcarbodiimide (0.183 mL, 1.18 
mmol), and 4-dimethylaminopyridine (0.017 g, 0.141 mmol). Compound 2b was isolated as an oil (303 
PJ\LHOG,5$75Ȟmax  2930, 2864, 1826, 1763, 1613, 1579, 1508 cm-1; 1H NMR (CDCl3, 500 
0+]į+GJ = 2.1 Hz), 7.00 (1H, d, J = 2.1 Hz), 6.84 (1H, d, J = 8.5 Hz), 6.50 (2H, s), 6.45 (2H, 
dd, J = 12.2 Hz), 5.42±5.32 (6H, m), 3.83 (3H, s), 3.79 (3H, s), 3.70 (6H, s), 2.81 (4H, t, J = 6.2 Hz), 2.52 
(2H, t, J = 7.5 Hz), 2.09±2.04 (4H, m), 1.71 (2H, quint., J = 7.4 Hz), 1.37±1.33 (8H, m), 0.97 (3H, t, J = 
7.5 Hz); 13C NMR (CDCl3, 0+]į
123.3, 112.1, 104.0, 61.0, 56.0, 34.0, 29.7, 29.3, 29.1, 25.7, 25.1, 20.6, 14.4; ESIMS m/z 578 [M+H]+; 
HRESIMS m/z 611.3134 [M+Cl]-; (calcd for C36H48O6Cl
-, 611.3140).  
     Arachidonic Acid Conjugate (2c). Compound 2c was prepared according to general method A using 
1 (0.045 g, 0.142 mmol), arachidonic acid (0.108 g, 0.355 mmol), N,N-diisopropylcarbodiimide (0.120 
mL, 0.355 mmol), and 4-dimethylaminopyridine (0.011 g, 0.042 mmol). Compound 2c was isolated as an 
oil (77 mg, 90% yield): ,5$75Ȟmax 3010, 2929, 2856, 1763, 1613, 1579, 1508 cm-1; 1H NMR (CDCl3, 
 500 MHz) į1H, d, J = 2.1 Hz), 7.00 (1H, d, J = 2.2 Hz), 6.84 (1H, d, J = 8.5 Hz), 6.50 (2H, s), 6.45 
(2H, dd, J = 12.2 Hz), 5.42±5.34 (8H, m), 3.83 (3H, s), 3.79 (3H, s), 3.70 (6H, s), 2.84±2.79 (6H, m), 2.54 
(2H, t, J = 7.5 Hz), 2.21±2.17 (2H, m), 2.07±2.03 (2H, m), 1.83 (2H, quint., J = 7.5 Hz), 1.36±1.28 (6H, 
m), 0.88 (3H, t, J = 6.8 Hz); 13C NMR (CDCl3, 0+]į
130.6, 130.2, 129.6, 129.0, 128.7, 128.4, 128.0, 127.7, 123.3, 112.1, 106.0, 61.0, 56.0, 33.5, 31.6, 29.4, 
27.3, 26.6, 25.7, 25.0, 22.7, 14.2;  ESIMS m/z 603 [M+H]+;  HRESIMS m/z 603.3676 [M+H]+ (calcd for 
C38H51O6
+, 603.3686). 
     Docosahexaenoic Acid Conjugate (2d). Compound 2d was prepared according to general method A 
using 1 (100 mg, 0.316 mmol), docosahexaenoic acid (100 mg, 0.304 mmol), N,N-
diisopropylcarbodiimide (0.097 mL, 0.632 mmol), and 4-dimethylaminopyridine (11 mg, 0.042 mmol). 
Compound 2d ZDVLVRODWHGDVDQRLOPJ\LHOG,5$75Ȟmax 3011, 2963, 2934, 2838, 2118, 
1764, 1579, 1508 cm-1; 1H NMR (CDCl3, 500 MHz) į1H, d, J = 2.2 Hz), 7.01 (1H, d, J = 2.1 Hz), 
6.84 (1H, d, J = 8.5 Hz), 6.50 (2H, s), 6.45 (2H, dd, J = 12.2 Hz), 5.45±5.36 (12H, m), 3.83 (3H, s), 3.79 
(3H, s), 3.70 (6H, s), 2.87±2.79 (10H, m), 2.60 (2H, t, J = 7 Hz), 2.51±2.47 (2H, m), 2.10±2.04 (2H, m), 
0.88 (3H, t, J = 7.5 Hz); 13C NMR (CDCl3, 0+]į
130.2, 129.6, 129.5, 128.7, 128.4, 128.21, 128.17, 128.0, 127.8, 127.7, 127.1, 123.3, 112.1, 106.0, 61.0, 
56.0, 33.9, 25.7, 22.9, 20.6, 14.4; ESIMS m/z 627 [M+]; HRESIMS m/z 661.3284 [M+Cl]- (calcd for 
C38H50O6Cl
-, 661.3296). 
     Cell Viability Assays. MCF-7 cells were cultured in DMEM supplemented with 10% heat inactivated 
FBS, penicillin, streptomycin, L-glutamine and 1 x MEM NEAA at 37 °C in a humidified incubator with 
a 5% CO2-containing atmosphere. Stock solutions of the compounds (1, 2a-d) were prepared in DMSO 
and diluted in DPBS to appropriate concentrations (0 -  ȝ0 0&)-7 cells (5000 cells/well) were 
seeded into 96-well plates. After 24 h, the medium was replaced by 100 µL of fresh medium and 5 µL of 
 appropriate compound diluted solutions (final: 0 - ȝ0$IWHUKLQFXEDWLRQDW&WKHVXSHUQDWDQWV
were removed and fresh medium without FBS was added (200 µL). MTS/PMS reagent (10 µL; 2/0.92 
mg/mL in DPBS) was added and the cells were left at 37 °C for 1 h. Absorbance was read at 490 nm on 
an Infinite M200 Pro spectrophotometer from Tecan. Viability was expressed as percentage of untreated 
control cells. IC50 values were determined graphically. Assays were performed using six replicates in three 
independent experiments. 
     Tubulin Assays. The assay was based on a Millipore tubulin polymerization kit. Stock solutions of the 
compounds (1, 2a-dZHUHSUHSDUHGLQ'062P0DQGGLOXWHGWRȝ0RUȝ0LQ deionized 
water. Fresh G-3%EXIIHUZDVSUHSDUHGE\PL[LQJȝ/RISRO\PHUL]DWLRQEXIIHU[3%ZLWKȝ/RI
P0*73LQGHLRQL]HGZDWHUȝ/DQGJO\FHUROȝ/$OOVROXWLRQVZHUHNHSWRQLFH7KHQ
ȝ/RIHDFKFRPSRXQGGLOXWHGVROXWLRQVZHUHadded to an ice-chilled 96-well plate (half-area). Next, 130 
ȝ/RIWXEXOLQVROXWLRQȝ0ZDVDGGHGWRWKH*-3%EXIIHUȝ/DQGȝ/RIWKLVGLOXWHGWXEXOLQ
solution were added to each well. Tubulin polymerization was followed at 37 °C by measuring the 
turbidity variation at 350 nm every 30 s for 2 h. Nocodazole and DMSO (1.43% or 0.14% v/v) were used 
as controls. Assays were performed in duplicate. 
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